RxDoctor Payments DataLook up a doctor →

Andy Rodriguez, MD

Clinical Neurophysiology · Livingston, NJNPI 1972820330

Payments from drug & device makers

$7,787in general payments, 2019–2025

Across 467 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • SK Life Science, Inc.$843
  • Supernus Pharmaceuticals, Inc.$772
  • UCB, Inc.$749
  • Neuropace, Inc.$538
  • Pfizer$402
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$7,764100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$253,636
Medicare patients
487
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate109$233,536
EpidiolexCannabidiol (Cbd)34$225,678
XcopriCenobamate85$130,680
ZonegranZonisamide20$127,210
Lamictal XrLamotrigine48$126,096
Keppra XrLevetiracetam48$113,164
BriviactBrivaracetam72$107,144
Lamotrigine ErLamotrigine127$92,460
LamictalLamotrigine58$71,304
OnfiClobazam24$66,747
TopamaxTopiramate47$58,327
FycompaPerampanel32$35,481
KeppraLevetiracetam27$34,513
NayzilamMidazolam43$31,261
Tiagabine Hcl16$31,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$380$233,536109 claims
UCB, Inc.Briviact, Nayzilam, Vimpat$749$160,884134 claims
SK Life Science, Inc.Xcopri$843$130,68085 claims
Lundbeck LLCOnfi$224$66,74724 claims
Eisai Inc.Fycompa$122$35,48132 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$772$23,63225 claims
PfizerNurtec Odt, Dilantin$402$18,71233 claims
Upsher-smith Laboratories LLCTopiramate$29$4,026150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Livingston

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →